PURPOSE: Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. EXPERIMENTAL DESIGN: Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival. RESULTS: Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months. CONCLUSIONS: This regimen is tolerable palliative option for patients with metastatic esophageal cancer.
PURPOSE: Experimental data, both in vivo and in vitro, suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. EXPERIMENTAL DESIGN:Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and cisplatin 100 mg/m(2) on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival. RESULTS: Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months. CONCLUSIONS: This regimen is tolerable palliative option for patients with metastatic esophageal cancer.
Authors: J R Kroep; G J Peters; C J van Moorsel; A Catik; J B Vermorken; H M Pinedo; C J van Groeningen Journal: Ann Oncol Date: 1999-12 Impact factor: 32.976
Authors: H Bleiberg; T Conroy; B Paillot; A J Lacave; G Blijham; J H Jacob; L Bedenne; M Namer; P De Besi; F Gay; L Collette; T Sahmoud Journal: Eur J Cancer Date: 1997-07 Impact factor: 9.162
Authors: Elisabeth I Heath; Susan Urba; John Marshall; Steven Piantadosi; Arlene A Forastiere Journal: Invest New Drugs Date: 2002-02 Impact factor: 3.850
Authors: A B Sandler; H L Kindler; L H Einhorn; E Mitchell; G Masters; M Kraut; S Nicol; D Raghavan Journal: Ann Oncol Date: 2000-09 Impact factor: 32.976
Authors: Byeong-Bae Park; Young-Hyuck Im; In Gyu Hwang; Sang Cheol Lee; Jin Seok Ahn; Myung-Ju Ahn; Ho-Yeong Lim; Won Ki Kang; Keunchil Park Journal: Invest New Drugs Date: 2008-03-27 Impact factor: 3.850
Authors: J Millar; P Scullin; A Morrison; B McClory; L Wall; D Cameron; H Philips; A Price; D Dunlop; M Eatock Journal: Br J Cancer Date: 2005-11-14 Impact factor: 7.640